Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever
BackgroundHay fever, characterized by seasonal allergic reactions, poses a significant health challenge. Existing therapies encompass standard drug regimens, biological agents, and specific immunotherapy. This study aims to assess and compare the effectiveness of anti-IgE (omalizumab), medication th...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1363034/full |
| _version_ | 1797293059042443264 |
|---|---|
| author | Rui Tang Xiaohong Lyu Yibo Hou Yongshi Yang Guodong Fu Liping Zhu Lu Xue Hong Li Ruiqi Wang |
| author_facet | Rui Tang Xiaohong Lyu Yibo Hou Yongshi Yang Guodong Fu Liping Zhu Lu Xue Hong Li Ruiqi Wang |
| author_sort | Rui Tang |
| collection | DOAJ |
| description | BackgroundHay fever, characterized by seasonal allergic reactions, poses a significant health challenge. Existing therapies encompass standard drug regimens, biological agents, and specific immunotherapy. This study aims to assess and compare the effectiveness of anti-IgE (omalizumab), medication therapy, and subcutaneous immunotherapy (SCIT) for hay fever.MethodsConducted as a retrospective cohort study, this research involved 98 outpatient hay fever patients who underwent routine medication, omalizumab treatment, or SCIT before the onset of the spring pollen season. A follow-up was performed one month after the start of the pollen season. The comprehensive symptoms and drug scores were used to evaluate patients with different intervention methods, facilitating a comparative analysis of therapeutic outcomes.ResultsCompared with before treatment, the symptoms of patients treated with the three methods were all significantly relieved, and the medication score were significantly reduced. Patients treated with omalizumab demonstrated higher symptoms and medication scores than SCIT group before treatment, but similar scores after treatment, which were both lower than medicine treatment group. After treatment with omalizumab or SCIT, patients in both groups had significantly lower medication scores than the medication group and were close to no longer using medication for symptom relief. The mountain juniper-sIgE was significantly higher after treatment than before treatment in both medicine treatment group and omalizumab treatment group.ConclusionOmalizumab and SCIT offer superior effects than medication therapy in hay fever patients. |
| first_indexed | 2024-03-07T20:07:27Z |
| format | Article |
| id | doaj.art-d08a4716161948b1ac0e3d9f4e80fbb9 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-07T20:07:27Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-d08a4716161948b1ac0e3d9f4e80fbb92024-02-28T04:56:56ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13630341363034Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay feverRui Tang0Xiaohong Lyu1Yibo Hou2Yongshi Yang3Guodong Fu4Liping Zhu5Lu Xue6Hong Li7Ruiqi Wang8Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaBackgroundHay fever, characterized by seasonal allergic reactions, poses a significant health challenge. Existing therapies encompass standard drug regimens, biological agents, and specific immunotherapy. This study aims to assess and compare the effectiveness of anti-IgE (omalizumab), medication therapy, and subcutaneous immunotherapy (SCIT) for hay fever.MethodsConducted as a retrospective cohort study, this research involved 98 outpatient hay fever patients who underwent routine medication, omalizumab treatment, or SCIT before the onset of the spring pollen season. A follow-up was performed one month after the start of the pollen season. The comprehensive symptoms and drug scores were used to evaluate patients with different intervention methods, facilitating a comparative analysis of therapeutic outcomes.ResultsCompared with before treatment, the symptoms of patients treated with the three methods were all significantly relieved, and the medication score were significantly reduced. Patients treated with omalizumab demonstrated higher symptoms and medication scores than SCIT group before treatment, but similar scores after treatment, which were both lower than medicine treatment group. After treatment with omalizumab or SCIT, patients in both groups had significantly lower medication scores than the medication group and were close to no longer using medication for symptom relief. The mountain juniper-sIgE was significantly higher after treatment than before treatment in both medicine treatment group and omalizumab treatment group.ConclusionOmalizumab and SCIT offer superior effects than medication therapy in hay fever patients.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1363034/fullhay feverOmalizumabsubcutaneous immunotherapyallergymedication |
| spellingShingle | Rui Tang Xiaohong Lyu Yibo Hou Yongshi Yang Guodong Fu Liping Zhu Lu Xue Hong Li Ruiqi Wang Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever Frontiers in Immunology hay fever Omalizumab subcutaneous immunotherapy allergy medication |
| title | Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever |
| title_full | Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever |
| title_fullStr | Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever |
| title_full_unstemmed | Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever |
| title_short | Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever |
| title_sort | comparison of the therapeutic effects of medication therapy specific immunotherapy and anti ige omalizumab in patients with hay fever |
| topic | hay fever Omalizumab subcutaneous immunotherapy allergy medication |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1363034/full |
| work_keys_str_mv | AT ruitang comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever AT xiaohonglyu comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever AT yibohou comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever AT yongshiyang comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever AT guodongfu comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever AT lipingzhu comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever AT luxue comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever AT hongli comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever AT ruiqiwang comparisonofthetherapeuticeffectsofmedicationtherapyspecificimmunotherapyandantiigeomalizumabinpatientswithhayfever |